Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time - Studies in repeated muscle biopsies
K. Amemiya et al., Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time - Studies in repeated muscle biopsies, BRAIN, 123, 2000, pp. 2030-2039
Inclusion body myositis (IBM) is an inflammatory myopathy characterized imm
unohistologically by prominent invasion of the non-necrotic, MHC-I class an
tigen-expressing muscle fibres by CD8+ cytotoxic T cells. If the autoinvasi
ve CD8+ T cells are recruited specifically to the muscle and play a primary
pathogenetic role in the disease, a clonal restriction persisting over tim
e should be anticipated. In this study, we analysed the T-cell receptor (TC
R) gene usage by endomysial T lymphocytes in three sequential muscle biopsi
es from three different IBM patients over a 19-22 month period using immuno
histochemistry, reverse transcription-polymerase chain reaction (RT-PCR) an
d sequence analysis of the complementarity determining region (CDR3) of the
amplified TCRs. We found that CD8+ T lymphocytes persist in the endomysial
infiltrates in all biopsies during a 19-22 month period. The most frequent
ly detected TCRs were the V beta 3, V beta 5.1, V beta 6.7 and V beta 13 ge
ne families, and several of the autoinvasive CB8+ T cells expressed the TCR
s V beta 6.7 and V beta 5.1. A restricted usage of the examined V beta 6 ge
ne family was found to persist in the complementarity CDR3 determining regi
on of the autoinvasive T cells over the 22 month period. Identical V beta 6
CDR3 gene arrangements were also found in the multiple muscle biopsies fro
m two of the three IBM patients. The results indicate that in IBM there is
a restricted expression of the TCR gene families among the autoinvasive T l
ymphocytes with homologies in the CDR3 region that persist over the course
of the disease. a continuous, antigen-driven T-cell response is prominent i
n the muscle of patients with IBM.